<DOC>
	<DOCNO>NCT00086957</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Combining gefitinib trastuzumab docetaxel may kill tumor cell . PURPOSE : This phase I/II trial study best dose docetaxel give together gefitinib trastuzumab treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Gefitinib , Trastuzumab , Docetaxel Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety efficacy gefitinib , trastuzumab ( Herceptin® ) , docetaxel , term time disease progression , patient HER2/neu-overexpressing metastatic adenocarcinoma breast . Secondary - Determine objective tumor response rate patient treat regimen . - Correlate expression and/or degree phosphorylation epidermal growth factor receptor , HER2/neu , c-fos , Akt , ERK½ , P13K , p53 , p21 , p27 outcome patient treat regimen . OUTLINE : This phase I , multicenter , dose-escalation study docetaxel follow phase II study . Patients stratify accord trastuzumab ( Herceptin® ) -naive vs trastuzumab-failure . - Phase I : Patients receive oral gefitinib daily day 2-14 . Patients also receive trastuzumab* IV 30-90 minute docetaxel IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . NOTE : *Trastuzumab give high dose ( load dose ) course 1 low dose subsequent course . Cohorts 3-6 patient receive docetaxel dose level 1 . If dose-limiting toxicity ( DLT ) observe first cohort 3 patient , dose docetaxel remain . If 1 DLT observe first cohort 3 patient , 3 additional patient add ( total 6 patient ) dose level 1 . If DLTs observe dose level 1 , dose docetaxel remain . If 2 3 2 6 patient experience DLT dose level 1 , dose docetaxel consider maximum tolerate dose ( MTD ) subsequently reduce . If 2 3 2 6 patient experience DLT reduce dose docetaxel , study stop . - Phase II : Patients receive docetaxel MTD gefitinib trastuzumab phase I . Patients follow survival . PROJECTED ACCRUAL : A total 3-76 patient accrue study within 26 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease HER2/neu overexpression ( 3+ immunohistochemistry OR 2+ fluorescence situ hybridization ) Measurable evaluable disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5.0 time ULN presence liver metastasis ) Bilirubin &lt; 1.5 time ULN No unstable uncompensated hepatic disease Renal Creatinine &lt; 1.6 mg/dL No unstable uncompensated renal disease Cardiovascular LVEF &gt; 45 % echocardiogram MUGA No prior New York Heart Association class IIV heart disease No prolong PR interval atrioventricular block ECG No unstable uncompensated cardiac disease Pulmonary No unstable uncompensated respiratory disease No clinically active interstitial lung disease Patients asymptomatic chronic stable radiographic change allow Immunologic No autoimmune disorder No condition immunosuppression No severe hypersensitivity taxane gefitinib excipients Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior concurrent malignancy within past 5 year except basal cell carcinoma carcinoma situ cervix No severe uncontrolled systemic disease No acute chronic medical condition would preclude study participation No significant clinical disorder laboratory find would preclude study participation No psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Prior adjuvant trastuzumab ( Herceptin® ) allow &gt; 6 month elapse disease recurrence No prior trastuzumab metastatic breast cancer No prior monoclonal antibody direct epidermal growth factor receptor ( EGFR ) Chemotherapy Prior adjuvant chemotherapy ( firstline therapy metastatic breast cancer ) allow Prior adjuvant taxane allow complete &gt; 6 month diagnosis metastatic breast cancer No prior docetaxel metastatic breast cancer Endocrine therapy Prior adjuvant hormonal therapy ( firstline therapy metastatic breast cancer ) allow No concurrent hormonal therapy Concurrent steroid allow provide dose stable Radiotherapy Not specify Surgery Fully recover prior oncologic major surgery No concurrent surgery within 7 day gefitinib administration Other Recovered prior anticancer therapy ( alopecia allow ) More 30 day since prior nonapproved drug investigational agent No prior EGFRdirected therapy ( i.e. , tyrosine kinase inhibitor ) No concurrent use follow medication : Phenytoin Carbamazepine Barbiturates Rifampin Hypericum perforatum ( St. John 's wort ) No concurrent anticancer therapy No concurrent cardioprotective drug No concurrent oral retinoids Concurrent participation City Hope indiumlabeled trastuzumab image study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>